Health and Fitness Health and Fitness
Mon, September 27, 2010
[ Mon, Sep 27th 2010 ] - Market Wire
Kindred Healthcare Acquires Three Nursing and Reh .. enters in Dallas-Fort Worth, Texas Cluster Market
[ Mon, Sep 27th 2010 ] - Market Wire
Alcon Announces Third Quarter 2010 Financial Release and Conference Call Dates
[ Mon, Sep 27th 2010 ] - Market Wire
Law Office of Brodsky & Smith, LLC Announces Investigation of NightHawk Radiology Holdings, Inc.
[ Mon, Sep 27th 2010 ] - Market Wire
Bioniche Experiences Increased Trading Activity
[ Mon, Sep 27th 2010 ] - Market Wire
Powers Taylor Law Firm Investigates NightHawk Rad .. rning the Acquisition by Virtual Radiologic Corp.
[ Mon, Sep 27th 2010 ] - Market Wire
Tenet Announces Lake Pointe Medical Center Appoints New Hospital CEO
[ Mon, Sep 27th 2010 ] - Market Wire
Valeant and Biovail Announce Results of Special Meetings of Shareholders
[ Mon, Sep 27th 2010 ] - Market Wire
Transcend Introduces its Next Generation Platform - ENCORE
[ Mon, Sep 27th 2010 ] - Market Wire
Kendall Law Group Investigates NightHawk Radiology Holdings Acquisition for Shareholders
[ Mon, Sep 27th 2010 ] - Market Wire
ROBERT BURGESS APPOINTED TO IMRIS BOARD OF DIRECTORS
[ Mon, Sep 27th 2010 ] - Market Wire
Aetna Signs Contract Extension with Crozer-Keystone Health System
[ Mon, Sep 27th 2010 ] - Market Wire
Sanofi Pasteur to Acquire VaxDesign, a U.S. Biotechnology Company
[ Mon, Sep 27th 2010 ] - Market Wire
Clark Marcus Appointed Sole Chief Executive Officer of Comprehensive Care Corporation
[ Mon, Sep 27th 2010 ] - Market Wire
ZIOPHARM Granted Japanese Patent for Darinaparsin
[ Mon, Sep 27th 2010 ] - Market Wire
Progenics Extends Agreement with Pfizer for RELISTOR Commercialization
[ Mon, Sep 27th 2010 ] - Market Wire
Trimeris and Roche Reach Agreement on Trimeris Repayment of Deferred Marketing Expense
[ Mon, Sep 27th 2010 ] - Market Wire
Hi-Tech Pharmacal Will Market Generic Buprenorphine HCl Sublingual Tablets
[ Mon, Sep 27th 2010 ] - Market Wire
Emergent BioSolutions to Participate in October 2010 Investor Conferences
[ Mon, Sep 27th 2010 ] - Market Wire
Media Advisory - Oncolytics Biotech(R) Inc. to Present at JMP Securities Healthcare Conference
[ Mon, Sep 27th 2010 ] - Market Wire
GenMark Diagnostics Selected as Diagnostic Platform in Warfarin Clinical Trial
[ Mon, Sep 27th 2010 ] - Market Wire
Rotech Healthcare Inc. Announces Proposed Private Offering of $225 Million Senior Secured Notes
[ Mon, Sep 27th 2010 ] - Market Wire
Seattle Genetics and Millennium Announce Positive .. (SGN-35) Data from Pivotal Trial in Relapsed and
[ Mon, Sep 27th 2010 ] - Market Wire
Wellstar Announces New Website
Sun, September 26, 2010
[ Sun, Sep 26th 2010 ] - Market Wire
Aetna ©largit le spectre des Options de son Plan de sant© en Afrique
[ Sun, Sep 26th 2010 ] - Market Wire
Aetna Expands Africa Health Plan Options
Sat, September 25, 2010
[ Sat, Sep 25th 2010 ] - Market Wire
ANGIOTECH ANNOUNCES THREE YEAR DATA FROM THE HORI .. IOR OUTCOMES WITH BOSTON SCIENTIFIC CORPORATION'S
Fri, September 24, 2010
[ Fri, Sep 24th 2010 ] - Market Wire
Harwood Feffer LLP Files Class Action On Behalf O .. c. Securities For The Enlarged Class Period March
[ Fri, Sep 24th 2010 ] - Market Wire
Novartis AG, Merck KGaA, Biogen Idec, Teva and Bed Bath & Beyond
[ Fri, Sep 24th 2010 ] - Market Wire
Allergan Receives FDA Approval for OZURDEX® as T .. ious Uveitis Affecting the Posterior Segment of t
[ Fri, Sep 24th 2010 ] - Market Wire
Seattle Genetics to Host Conference Call and Webc .. arding Top-line Data from Brentuximab Vedotin (SG

Seattle Genetics to Host Conference Call and Webcast on September 27, 2010 Regarding Top-line Data from Brentuximab Vedotin (SG


Published on 2010-09-24 13:20:54 - Market Wire
  Print publication without navigation


SEATTLE--([ BUSINESS WIRE ])--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its management will host a conference call and webcast on Monday, September 27, 2010, at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET) regarding top-line results from its brentuximab vedotin (SGN-35) pivotal clinical trial in Hodgkin lymphoma.

The live event will be available from Seattle Geneticsa™ website at [ www.seattlegenetics.com ], under the Investors and News section, or by calling (877) 941-8631 (domestic) or (480) 629-9819 (international). The access code is 4369251. A replay of the discussion will be available beginning at approximately 7:00 a.m. PT / 10:00 a.m. ET on September 27, 2010 from Seattle Geneticsa™ website or by calling (800) 406-7325 (domestic) or (303) 590-3030 (international), using access code 4369251. The replay will be available through October 1, 2010.

About Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The companya™s lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the U.S. Food and Drug Administration. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, MedImmune, a subsidiary of AstraZeneca, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at [ www.seattlegenetics.com ].

Contributing Sources